SS-31 · Mitochondria-Targeted Tetrapeptide · Protocol Guide
Elamipretide (SS-31): The Cardiolipin Stabilizer Guide
Elamipretide is a mitochondrial-targeted peptide with one of the strongest preclinical rationales in this category. Phase III trials have been mixed. The compound is now FDA-relevant. This guide separates the science from the speculation.
FDA Status
Late-Stage Development (Barth Syndrome)
Pharmacy
Optimal Balance Pharmacy (503A licensed)
Medical Service
RxPepsDirect, physician-supervised
Access
33 U.S. States
Our promise: Elamipretide has the cleanest mitochondrial-targeting mechanism in this category and a mixed clinical trial record. Phase III in age-related macular degeneration and Barth syndrome have produced different signals. We do not gloss over either.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.Section 01
What Elamipretide Actually Is
Elamipretide is a 4-amino-acid synthetic peptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) developed by the Szeto-Schiller lab at Cornell. Trade name Bendavia, research designation SS-31. It is the most-pharmacologically-elegant compound in the mitochondrial-support category: it selectively concentrates 1000-fold in the inner mitochondrial membrane and binds cardiolipin, a phospholipid critical to electron transport chain function.
Stealth BioTherapeutics has pursued FDA approval through multiple Phase III programs. Barth syndrome (a rare cardiomyopathy with cardiolipin remodeling failure) has been the most active path. Age-related macular degeneration trials produced mixed results. The compound is mechanistically clean, but the clinical translation has been harder than the preclinical data suggested.
4
Amino acids. One of the smallest mitochondria-targeted peptides in clinical use.
1000x
Concentration in inner mitochondrial membrane vs cytoplasm
Cardiolipin
Selective binding target. Critical phospholipid for electron transport.
Section 02
Who It Is Actually For
| Profile | Goal | Fit |
|---|---|---|
| Documented mitochondrial dysfunction (post-viral, chronic illness) | Cardiolipin stabilization, ETC efficiency restoration | Strong Fit |
| Cardiometabolic optimization (40+, heart failure prevention) | Cardiac mitochondrial support | Adjunct Use |
| Longevity biohacker with mitochondrial focus | Stack with NAD+ and MOTS-c for comprehensive mitochondrial support | Speculative |
| Suspected Barth syndrome or rare mitochondrial disease | Cardiolipin remodeling defect treatment | Specialist Coordination |
| Active cancer (cardiolipin and mitochondrial biogenesis) | Mitochondrial support may benefit malignant cells | Physician Decision Only |
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Section 03
How It Works
Elamipretide carries a 3-plus charge under physiological conditions and is electrostatically attracted to the negatively charged inner mitochondrial membrane. Once there, it binds cardiolipin and stabilizes the phospholipid environment around electron transport chain complexes. The downstream effects: improved ETC supercomplex assembly, reduced electron leak (less reactive oxygen species generation), and preserved ATP production.
Section 04
Realistic Expectations
No Acute Signal Expected
Elamipretide does not produce a next-day subjective effect. The compound operates at the mitochondrial membrane level and effects accumulate over weeks.
Cumulative Mitochondrial Effect
Patients with documented mitochondrial dysfunction may begin to notice improved exercise tolerance, reduced post-exertional malaise, and cognitive clarity. Healthy adults may notice nothing during this window.
Full Protocol Effect
Phase III trials assessed effect at 6-month endpoints. The most positive signals appeared in this window for the patient populations who responded. Non-response is common.
Section 05
Dosing Protocol
| Context | Dose | Frequency | Evidence Basis |
|---|---|---|---|
| RxPepsDirect Standard | 3 mg (20 units) subcutaneous | Daily or 5 days per week | Clinical Practice |
| Phase III Barth Syndrome Trial | 40 mg subcutaneous (specific disease state) | Daily | Phase III |
| Phase II Macular Degeneration | 40 mg | Daily, 24-week course | Mixed Results |
Context
Dose
Frequency
Evidence Basis
Context
Dose
Frequency
Evidence Basis
Context
Dose
Frequency
Evidence Basis
Subcutaneous injection into abdominal fat. Standard insulin syringe (28 to 31 gauge, 6 to 8 mm needle). Morning timing is preferred to align with daily energy demand. The clinical trial doses are substantially higher than the RxPepsDirect off-label protocol because they targeted specific severe disease states.
Section 06
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 07
Stacking
Pairs Well With
NAD+ injectable
Different layer of the mitochondrial system (redox cofactor). Complementary to elamipretide's membrane stabilization.
MOTS-c
AMPK activation. Different mechanism, complementary mitochondrial support.
Coenzyme Q10 (oral)
Native electron carrier. The full mitochondrial-support stack often includes CoQ10 alongside elamipretide.
Methylene blue (low-dose)
Electron carrier bypass. Some practitioners combine these for severe mitochondrial dysfunction.
Approach With Caution
Active cancer
Mitochondrial support can benefit malignant cells. Oncologist clearance required.
Pregnancy / lactation
No safety data. Avoid.
Severe renal impairment
Elamipretide is renally cleared. Physician oversight on dose required.
Self-titration above prescribed dose
Phase III data used much higher doses for specific severe diseases. Higher does not mean better for off-label use.
Section 08
Pricing
Who You Pay, and What For
Pharmacy: Medication
$100 per 75 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect.
Section 09
Legal Access in 33 States
503A Licensed Pharmacy
Optimal Balance Pharmacy
Physician Prescription Required
Compounded medication, Rx only
Off-Label, Legal Practice
Not FDA-approved at retail, prescribable through compounding
Late-Stage FDA Program
Stealth BioTherapeutics Barth syndrome pursuit
Elamipretide does not yet have full FDA approval at retail. Compounded elamipretide remains available through 503A patient-specific compounding under physician prescription. If full FDA approval lands at some point in the next few years, the regulatory landscape will likely shift toward the branded finished form and compounded availability may change accordingly.
Section 10
Community Q&A
SS-31 and Elamipretide are the same?
Yes. SS-31 is the Szeto-Schiller research designation. Elamipretide is the international nonproprietary name. Bendavia was an earlier trade name. Same molecule.
Do I need this in addition to NAD+ and MOTS-c?
Mechanism is different. Elamipretide stabilizes the inner mitochondrial membrane. NAD+ provides redox cofactor. MOTS-c activates AMPK. They target different layers of the same system. Most longevity-focused patients pick one or two rather than stacking all three.
Will my insurance cover this?
No. Compounded medications are typically not covered by insurance. You pay the pharmacy directly for the medication and pay RxPepsDirect directly for the medical visit.
Will this go away if FDA approves a branded version?
Possibly. Historically, when a finished form gains FDA approval, compounding access for the same molecule can narrow under FDA policy. RxPepsDirect will communicate any access changes to active patients well in advance.
What if Optimal Balance is out of stock?
Your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 11
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your elamipretide under a patient-specific prescription, USP <797> sterile compounding standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for contraindications, designs the protocol, and writes the prescription.
Transparent Safety Communication
The guide flags the mixed Phase III track record, the cancer contraindication, and the regulatory uncertainty if FDA approval lands. We do not hide limitations.
Legal Access in 33 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PMID: 24446857
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021. PMID: 33564154
- Mischley LK, Shankland E, Liu SZ, et al. ATP and NAD+ Deficiency in Parkinson's Disease. Nutrients. 2023. PMID: 37049533
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Mitochondrial-derived peptide (metabolic)
MOTS-c protocol guide: AMPK activation, the WADA prohibition, and the human evidence gap
Strong rodent data, thin human RCT data. AMPK activator (different mechanism than metformin). WADA prohibited since 1/1/2025. Not an exercise substitute.
Longevity coenzyme
NAD+ protocol guide: sirtuin activation, the bioavailability problem, and IV vs subcutaneous
Oral supplements have a bioavailability problem the marketing rarely admits. IV produces the flush. Subcutaneous is the at-home middle ground. Not proven to extend lifespan.
Mitochondrial cognitive capsule (MB-5 to MB-25)
Methylene Blue guide: mitochondrial electron carrier, MAO-A inhibitor, the SSRI contraindication
Mitochondrial electron carrier at low dose, MAO-A inhibitor at any dose. SSRIs, SNRIs, MAOIs, TCAs are hard contraindications. Hormetic dose curve. Medication screening is mandatory.